More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained
According to Investing.com, Cathie Wood’s ARK ETFs bought Intellia Therapeutics (NTLA) on Monday, totaling over 263,848 shares worth more than $3.5 million via ARKK and ARKG, while selling 50,312 Rocket Lab (RKLB) shares worth over $4 million via ARKQ. NTLA reported positive Phase 3 results for lonvo-z and plans FDA rolling BLA and a potential 1H 2027 launch.
How this was made
The 30-second read
Why it matters
For NTLA, the combination of positive Phase 3 results, rolling BLA submission, and a potential 1H 2027 launch window creates a concrete catalyst stack that can support bullish positioning. For RKLB, the trade is framed as gain-taking after a large run, but without new company-specific fundamentals, the impact is likely sentiment-driven rather than thesis-changing.
Market read
This is primarily an ETF flow and sentiment narrative anchored to NTLA’s clinical and FDA milestones; RKLB is mainly a trimming/gain-taking story.
What to watch
The article does not provide details on the timing of the Phase 3 report relative to the trade, nor does it include any new RKLB-specific catalyst beyond the sale and recent launch activity.
Background
The piece describes ARK Investment Management’s Monday ETF trades, buying NTLA and selling RKLB, and ties NTLA to recent Phase 3 and FDA BLA actions.
Ticker impact
ARK bought Intellia Therapeutics shares after NTLA reported positive Phase 3 results for lonvo-z in hereditary angioedema and initiated rolling BLA.
Near-term upside bias as traders may front-run FDA review and potential 1H 2027 launch expectations.
The text provides specific clinical and regulatory milestones (Phase 3 positive, rolling BLA, potential 1H 2027 launch) plus a contemporaneous fund buying story, which can influence momentum and sentiment.
ARK sold Rocket Lab shares via ARKQ while RKLB stock has surged over 262% in the last year, implying gain-taking after a rally.
Limited immediate fundamental impact, but could add short-term selling pressure if traders treat it as a signal.
The only concrete RKLB-specific facts are the sale size and the stock’s prior-year surge; no new RKLB operational, regulatory, or financial catalyst is disclosed.
Market effects
Reinforces momentum in gene-editing/CRISPR names where clinical readouts and FDA pathway progress can drive ETF-driven flows.
None specified.
None specified.
Counterpoint
ARK’s trades may reflect portfolio rebalancing or risk management rather than a new view on NTLA or RKLB fundamentals.
Key entities
- companyIntellia Therapeutics
CRISPR/Cas9 gene-editing company; reported positive Phase 3 results for lonvo-z, initiated rolling BLA, and is preparing for potential 1H 2027 U.S. launch.
- companyRocket Lab
Small satellite launch services provider; ARK sold shares via ARKQ while the stock has surged over the past year.
- asset_managerARK Investment Management
Filed/managed ARK ETFs that bought NTLA and sold RKLB in the described trades.
